Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.31 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25754248 | 0.92 | KMT2A (0.36) | KMT2AHRH3PSMB1PSMB5KDM4E | |
| SCHEMBL25754503 | 0.90 | HRH3 (0.32) | KMT2AHRH3LMNAPSMB1PSMB5 | |
| SCHEMBL25754252 | 0.89 | KDM4E (0.38) | KMT2AHRH3PSMB1PSMB5KDM4E | |
| SCHEMBL25754504 | 0.85 | HRH3 (0.31) | HRH3LMNA | |
| SCHEMBL25754526 | 0.85 | KMT2A (0.37) | KMT2AKDM4EALDH1A1MEN1 | |
| SCHEMBL25754506 | 0.85 | KMT2A (0.38) | KMT2AKDM4EALDH1A1MEN1 | |
| SCHEMBL25754498 | 0.82 | HRH3 (0.33) | KMT2AHRH3LMNAPSMB1PSMB5 | |
| SCHEMBL25754249 | 0.80 | HRH3 (0.38) | KMT2AHRH3PSMB1PSMB5KDM4E | |
| SCHEMBL25754591 | 0.80 | HRH3 (0.38) | KMT2AHRH3PSMB1PSMB5KDM4E | |
| SCHEMBL25754394 | 0.80 | HRH3 (0.35) | HRH3LMNAPSMB1PSMB5KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | UCHL3, UBE2L3, ADAM33 | KMT2A 1974/4885HRH3 1596/4885LMNA 1517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.